Showing 6531-6540 of 7463 results for "".
- Lupin Launches Generic Clobetasol Cream in the UShttps://practicaldermatology.com/news/lupin-launches-generic-clobetasol-cream-in-the-us/2457637/Lupin has launched its Clobetasol Propionate Cream 0.05%, having received approval from the FDA earlier.
- MC2 Therapeutics Reports Positive Topline Data for Investigational Topical for Psoriasishttps://practicaldermatology.com/news/mc2-therapeutics-reports-positive-topline-data-for-investigational-topical-for-psoriasis/2457641/MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics A/S achieved its primary and secondary endpoints, according to recently reported top-line data from the US Phase 3 study. Results of the
- Whale of a Tale: Shark Gets Botox Injectionshttps://practicaldermatology.com/news/whale-of-a-tale-shark-gets-botox-injections/2457642/It may sound fishy, but even sharks can benefit from Botox injections. Charles E. Crutchfield III, MD, and Crutchfield Dermatology in Eagan, MN recently assisted the veterinary staff at Minnesota Zoo in Apple Valley with a unique patient. Haps, a sand tiger shark, had
- Merix Pharmaceutical Corp: Releev Cold Sore Treatment Now in Convenience Storeshttps://practicaldermatology.com/news/merit-pharmaceutical-corp-releev-cold-sore-treatment-now-in-convenience-stores/2457644/Merix Pharmaceutical Corp’s Releev®1 Day Cold Sore Symptom Treatment is now available in convenience stores, including 7-Eleven and soon in Circle K in the United States. Releev
- Ortho Dermatologics Resubmits NDA for Duobrii Lotionhttps://practicaldermatology.com/news/ortho-dermatologics-resubmits-nda-for-duobrii-lotion/2457646/Ortho Dermatologics, a division of Bausch Health Companies Inc., has resubmitted a New Drug Application (NDA) to the FDA for Duobrii™ (halobetasol propionate and tazarotene; IDP-118) lotion in the treatment of p
- "Phenomenal Gains" in Derm Device Market, Global Market Insights Predictshttps://practicaldermatology.com/news/phenomenal-gains-in-derm-device-market-global-market-insights-predicts/2457645/Dermatology devices market, an integral vertical of medical equipment space, of late, has been providing lucrative opportunities to the investors to exploit economies of scale. The claim is very well validated from the increasing attempts by the market giants to brainstorm innovative products tha
- Revision Skincare Launches DEJ Eye Cream, DEJ Face Creamhttps://practicaldermatology.com/news/revision-launches-dej-eye-cream-dej-face-cream/2457648/Revision Skincare® has created two comprehensive products,DEJ eye cream® and DEJ face cream®, utilizing Pathway Technology and Prebiotic Innovation to provide clinically-proven results and promote long-term skin health, the company says. DEJ eye cream® addresses
- Burt's Bees Nature-Based Sensitive Skin Care Outperforms MD-Recommended Regimenhttps://practicaldermatology.com/news/burts-bees-nature-based-sensitive-skin-care-outperforms-md-recommended-regimen/2457650/Burt’s Bees nature-based sensitive skin regimen is well-tolerated as well as clinically and statistically superior to a leading dermatologist-recommended synthetic regimen, according to a
- Frequent BCC Linked to Other Cancershttps://practicaldermatology.com/news/frequent-bcc-linked-to-other-cancers/2457651/Basal cell carcinoma may increase risk for the development of other cancers, including blood, breast, colon and prostate cancers, according to a preliminary study by researchers at the Stanford University School of Medicine. "We discovered that people who develop six or more basal ce
- Castle Creek Pharmaceuticals Gets FDA Fast Track Designation for Diacerein 1% Ointment for EBShttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-gets-fda-fast-track-designation-for-diacerein-1-ointment-for-ebs/2457655/The U.S. Food & Drug Administration (FDA) granted fast track status to Castle Creek Pharmaceuticals, LLC’s diacerein 1%, ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS). "Fast Track designation is an